TABLE OF CONTENTS
EXECUTIVE SUMMARY 2
MARKET OVERVIEW 7
Market definition 7
Research highlights 8
Market analysis 9
MARKET VALUE 10
MARKET SEGMENTATION I 11
MARKET SEGMENTATION II 12
MARKET SHARE 13
FIVE FORCES ANALYSIS 14
Summary 14
Buyer power 16
Supplier power 18
New entrants 19
Substitutes 21
Rivalry 23
LEADING COMPANIES 24
Novartis AG 24
Pfizer Inc. 28
Roche Holding AG 32
Sanofi-Aventis SA 36
MARKET FORECASTS 40
Market value forecast 40
APPENDIX 42
Methodology 42
Industry associations 43
Related Datamonitor research 43
Disclaimer 44
ABOUT DATAMONITOR 45
Premium Reports 45
Summary Reports 45
Datamonitor consulting 45
LIST OF TABLES
Table 1: Global pharmaceuticals, biotechnology & life sciences industry value: $ billion, 2005–09 10
Table 2: Global pharmaceuticals, biotechnology & life sciences industry segmentation I:% share, by value, 2009 11
Table 3: Global pharmaceuticals, biotechnology & life sciences industry segmentation II: % share, by value, 2009 12
Table 4: Global pharmaceuticals, biotechnology & life sciences industry share: % share, by value, 2009 13
Table 5: Novartis AG: key facts 24
Table 6: Novartis AG: key financials ($) 25
Table 7: Novartis AG: key financial ratios 26
Table 8: Pfizer Inc.: key facts 28
Table 9: Pfizer Inc.: key financials ($) 29
Table 10: Pfizer Inc.: key financial ratios 30
Table 11: Roche Holding AG: key facts 32
Table 12: Roche Holding AG: key financials ($) 33
Table 13: Roche Holding AG: key financials (CHF) 34
Table 14: Roche Holding AG: key financial ratios 34
Table 15: Sanofi-Aventis SA: key facts 36
Table 16: Sanofi-Aventis SA: key financials ($) 37
Table 17: Sanofi-Aventis SA: key financials (€) 37
Table 18: Sanofi-Aventis SA: key financial ratios 38
Table 19: Global pharmaceuticals, biotechnology & life sciences industry value forecast: $ billion, 2009–14 40
LIST OF FIGURES
Figure 1: Global pharmaceuticals, biotechnology & life sciences industry value: $ billion, 2005–09 10
Figure 2: Global pharmaceuticals, biotechnology & life sciences industry segmentation I:% share, by value, 2009 11
Figure 3: Global pharmaceuticals, biotechnology & life sciences industry segmentation II: % share, by value, 2009 12
Figure 4: Global pharmaceuticals, biotechnology & life sciences industry share: % share, by value, 2009 13
Figure 5: Forces driving competition in the global pharmaceuticals, biotechnology & life sciences industry, 2009 14
Figure 6: Drivers of buyer power in the global pharmaceuticals, biotechnology & life sciences industry, 2009 16
Figure 7: Drivers of supplier power in the global pharmaceuticals, biotechnology & life sciences industry, 2009 18
Figure 8: Factors influencing the likelihood of new entrants in the global pharmaceuticals, biotechnology & life sciences industry, 2009 19
Figure 9: Factors influencing the threat of substitutes in the global pharmaceuticals, biotechnology & life sciences industry, 2009 21
Figure 10: Drivers of degree of rivalry in the global pharmaceuticals, biotechnology & life sciences industry, 2009 23
Figure 11: Novartis AG: revenues & profitability 26
Figure 12: Novartis AG: assets & liabilities 27
Figure 13: Pfizer Inc.: revenues & profitability 30
Figure 14: Pfizer Inc.: assets & liabilities 31
Figure 15: Roche Holding AG: revenues & profitability 35
Figure 16: Roche Holding AG: assets & liabilities 35
Figure 17: Sanofi-Aventis SA: revenues & profitability 38
Figure 18: Sanofi-Aventis SA: assets & liabilities 39
Figure 19: Global pharmaceuticals, biotechnology & life sciences industry value forecast: $ billion, 2009–14 41
[Cerrar la tabla de contenidos]
